Verified at the source · FDA · EMA · CDSCO

Healthcare innovation goes in.
Verified, matched. It moves.

Every product, service and breakthrough is checked against the regulator itself. Then AI carries it to the exact doctors, hospitals and distributors who need it.

Unverified in · verified out · matched · every hand-raise tracked back to the maker
Enter the platform → Publish a breakthrough Explore breakthroughs
openFDAClinicalTrials.govEU EUDAMEDCDSCO IndiaWHO ICTRP openFDAClinicalTrials.govEU EUDAMEDCDSCO IndiaWHO ICTRP
One verified chain

Listed. Verified. Matched. Moved.

The maker lists it
Device · drug · service
Canipus verifies it
At the regulator itself
AI matches it
Specialty · territory · need
The right people act
Tracked hand-raises
Two sides, one rail

Built for the people who make it, and the people who use it.

For innovators & makers
Your innovation, carried to its people
Listing Verified ✓ Leads back
  • One ID in. Canipus pulls the regulator record itself · no manual entry
  • Precision reach. AI matches by specialty, condition and territory · never spray and pray
  • Nothing lost. Every doctor hand-raise returns to you as a tracked lead
List your innovation →
For doctors & hospitals
A feed you can finally trust
Your feed Source linked Your review
  • Verified only. Every card carries its regulator proof, linked at the source
  • Ask in your own words. AI finds the exact device or service, gated to your specialty and city
  • Publish and lead. Posts, clinician reviews and specialty communities of your own
Enter the doctor portal →
The core four

Two bring innovation. Two adopt it. Canipus connects them, precisely.

● Supply · they bring itDemand · they adopt it ●
Both supply hands reach the same doctors & hospitals, matched by specialty, condition and territory. Every hand-raise flows back as a tracked lead.
How verification works

Two lanes in. One standard out.

The maker enters one ID
K241335NCT05662241
Status · Active ✓ Phase / Class ✓ Sponsor & dates ✓
Canipus pulls the full record from the source · no manual entry
Automated · live registry API
IDNCT05662241
INDIGO Phase 3 · IgG4-related diseaserecord pulled live from ClinicalTrials.gov ✓
openFDA ✓
ClinicalTrials.gov ✓
Type an FDA / NCT number. Canipus pulls the record itself
AI + human review
CDSCO India ✓
EMA · EUDAMED ✓
AI drafts · a specialist confirms
Canipus AI verification
Verified · source linked on every card
Precision matching

One innovation. Exactly its people.

Verified innovation
Transcatheter heart valve
FDA cleared ✓CardiologyClass IIIIndia launch
Canipus AI matching
Interventional cardiologistmatched ✓
Hospital · cath-lab procurementmatched ✓
Distributor · cardiac devices · Westmatched ✓
Dermatologist✕
General pharmacy✕
Matched on specialty · territory · tier · verified status · every hand-raise tracked back to the maker
The doctor’s dashboard

Doctors don’t just browse here. They publish.

Publish your knowledge
Posts with video & images. AI lays it out, your words verbatim
Repost with your thoughts
Clinician reviews on any product or service, with your video explanation
Reach the right patients
Disease-specific posts on advanced treatments find the people living with it
Peers & communities
Connect by specialty. Build the rooms where your field talks
See the doctor portal →
Built for every side of healthcare

Nine roles. One trust layer.

Doctor Manufacturer Patient or Caregiver Distributor Biotechnology PharmaceuticalComing soon Research or ScientistComing soon PhysiotherapistComing soon Other healthcare ProfessionalComing soon
Live on Canipus

Every card carries its proof.

Latest verifiedIn trials
Obexelimab: non-depleting B-cell antibody for IgG4-related disease
Zenas BioPharma · Rheumatology / Immunology · USA
ClinicalTrials.gov · INDIGO Phase 3 · matched at the source
Explore verified breakthroughs →